KNSA
Kiniksa Pharmaceuticals Ltd. Class A · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website kiniksa.com
- Employees(FY) 220
- ISIN BMG5269C1010
Performance
-2.08%
1W
+13.23%
1M
-0.85%
3M
+27.55%
6M
+12.71%
YTD
+44.84%
1Y
Profile
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that completed Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Investment Analysis Report: KNSA
Overview:
KNSA is a company operating in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company has a market capitalization of $706,069,617. In this report, we will conduct a comprehensive analysis of KNSA's financial health, earnings and revenue growth, profitability, oper...
Technical Analysis of KNSA 2024-05-10
Overview:
In analyzing the technical indicators for KNSA over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for informed deci...
Recent News & Updates
- 2024-05-07 16:01
- 2024-05-07 04:01
- 2024-04-26 06:37
- 2024-04-24 13:36
- 2024-04-24 09:00
- 2024-04-23 21:00
- 2024-04-23 08:53
- 2024-04-23 08:40
- 2024-04-23 07:30
- 2024-04-22 23:53
- 2024-04-22 20:40
- 2024-04-22 20:36
Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises(Yahoo Finance)
- 2024-04-22 19:30
- 2024-04-16 16:01
- 2024-04-16 04:01
- 2024-04-02 07:30
- 2024-04-01 19:30
- 2024-03-04 13:23
- 2024-03-01 09:55
- 2024-03-01 05:17
Kiniksa Pharmaceuticals Full Year 2023 Earnings: Beats Expectations(Simply Wall St.)
- 2024-02-29 23:33
- 2024-02-29 20:55
- 2024-02-29 12:00
- 2024-02-29 09:21
- 2024-02-28 23:00
- 2024-02-28 20:21
- 2024-02-28 08:50
- 2024-02-28 08:40
- 2024-02-28 07:30
- 2024-02-27 19:50
Page 1 of 5
previousnext